Search results
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 4 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Is It Too Late to Buy Pfizer Stock? | The Motley Fool
The Motley Fool· 3 days agoAre Pfizer's (PFE -0.43%) best days behind it? If the stock's critics are to be believed, the answer...
Pfizer (NYSE:PFE) Stock Price Down 0.9%
ETF DAILY NEWS· 3 days agoPfizer Inc. (NYSE:PFE – Get Free Report) was down 0.9% during trading on Thursday . The company traded as low as $27.20 and last traded at $27.41. Approximately 11,513,196 ...
Pfizer Inc. (NYSE:PFE) Position Increased by V Square Quantitative Management LLC
ETF DAILY NEWS· 2 days agoV Square Quantitative Management LLC increased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 260.1% in the 4th quarter, according to the company in its ...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 5 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 4 days agoPfizer disclosed on May 7 that a child participating in another...
Raleigh Capital Management Inc. Sells 2,270 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 2 days agoRaleigh Capital Management Inc. cut its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 3.4% in the fourth quarter, according to the company in its most recent disclosure ...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 5 days agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 5 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 4 days agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
